ProQR Therapeutics
PRQR
63 hedge funds and large institutions have $259M invested in ProQR Therapeutics in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 21 closing their positions.
70% more call options, than puts
Call options by funds: $877K | Put options by funds: $516K
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
2% less funds holding
Funds holding: 64 → 63 (-1)
9% less capital invested
Capital invested by funds: $286M → $259M (-$27M)
26.2% less ownership
Funds ownership: 86.28% → 60.08% (-26%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rafferty Asset Management
New York
|
+$3.78M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.44M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$3.34M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$2.39M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14M |
| 2 |
Citigroup
New York
|
-$11.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.1M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$4.71M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.1M |
PRQR Hedge Fund Activity: Q2 2021 in Review
63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2021, worth a combined $259M — down 9.4% from $286M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of PRQR and 20 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 15 added.
The largest buyer was Rafferty Asset Management, opening a new position worth an estimated $3.78M. The largest seller was RA Capital Management, exiting entirely with an estimated $14M sold.
- 63 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2021, down from 64 in Q1 2021.
- Funds reported $259M of ProQR Therapeutics stock for Q2 2021, down 9.4% quarter-over-quarter.
- 20 funds opened new ProQR Therapeutics positions in Q2 2021 and 21 closed out, a net change of -1 holder.
- The largest ProQR Therapeutics buyer in Q2 2021 was Rafferty Asset Management, an estimated $3.78M added.
- The largest ProQR Therapeutics seller in Q2 2021 was RA Capital Management, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2021.